KRYS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

105.97M

+16.27%

1.474

-3.68%

120.26M

+36.37%

1.520

+26.67%

138.92M

+44.64%

1.938

+50.19%

Estimates Revision

The market is revising Upward the revenue expectations for Krystal Biotech, Inc. (KRYS) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 57.50%.

Revenue Estimates for FY2025

Revise Upward

+1.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+24.45%

In Past 3 Month

Stock Price

Go Up

+57.50%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 245.240

Low

198.00

Averages

221.00

High

255.00

Current: 245.240

Low

198.00

Averages

221.00

High

255.00

Citi

Yigal Nochomovitz

Neutral

maintain

$166 -> $198

2025-11-04

Reason

Citi

Yigal Nochomovitz

Price Target

$166 -> $198

2025-11-04

maintain

Neutral

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $198 from $166 and keeps a Neutral rating on the shares following the Q3 report. Citi views the shares as fairly valued but believes Krystal is well positioned into its 2026 pipeline readouts.

Clear Street

Buy

maintain

$212 -> $217

2025-11-03

Reason

Clear Street

Price Target

$212 -> $217

2025-11-03

maintain

Buy

Reason

Clear Street raised the firm's price target on Krystal Biotech to $217 from $212 and keeps a Buy rating on the shares after Krystal reported Q3 results. The firm, which see Vyjuvek as having steadied in the U.S. and near term growth to be driven by international launches, increased its FY25 revenue estimate to $383M and decreased its expense estimates in line with guidance.

Chardan

Buy

maintain

$216 -> $220

2025-11-03

Reason

Chardan

Price Target

$216 -> $220

2025-11-03

maintain

Buy

Reason

Chardan raised the firm's price target on Krystal Biotech to $220 from $216 and keeps a Buy rating on the shares. The company's Q3 net Vyjuvek revenue topped estimates as results included a contribution from the recent launch in Germany, the analyst tells investors in a research note. Krystal has also reported an improved gross margin of 96% and "stable" gross-to-net ratio with previous quarters, the firm added.

BofA

NULL -> Buy

maintain

$182 -> $255

2025-10-17

Reason

BofA

Price Target

$182 -> $255

2025-10-17

maintain

NULL -> Buy

Reason

BofA raised the firm's price target on Krystal Biotech to $255 from $182 and keeps a Buy rating on the shares. The firm, which continues to like Vyjuvek, Krystal's drug treating the rare skin condition dystrophic epidermolysis bullosa, also adjusts its pipeline and platform contribution estimates to add standalone revenue builds for KB801 and KB803 as it believes near-term pipeline data could be "value unlocking."

Guggenheim

Debjit Chattopadhyay

NULL -> Buy

maintain

$189 -> $224

2025-10-17

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$189 -> $224

2025-10-17

maintain

NULL -> Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Krystal Biotech to $224 from $189 and keeps a Buy rating on the shares. The firm, which anticipates Krystal will be able to return to about 50 total new PSF per quarter during Q2, anticipates an equilibrium between efficacy-driven drop in compliance and new patient adds by year-end 2025, the analyst tells investors in a preview.

Chardan

Buy

maintain

$219 -> $216

2025-08-22

Reason

Chardan

Price Target

$219 -> $216

2025-08-22

maintain

Buy

Reason

Chardan lowered the firm's price target on Krystal Biotech to $216 from $219 and keeps a Buy rating on the shares after the company announced it will be prioritizing the development of inhaled KB707 for the treatment of non-small cell lung cancer and de-prioritizing the development of KB707 in the intratumoral setting. In conjunction with the prioritization of inhaled KB707, Krystal has paused enrollment in the intratumoral OPAL-1 trial, notes the analyst, who expects additional color on the go forward plan and an update on FDA interactions with Q3 earnings due in November.

Valuation Metrics

The current forward P/E ratio for Krystal Biotech Inc (KRYS.O) is 34.65, compared to its 5-year average forward P/E of -14.94. For a more detailed relative valuation and DCF analysis to assess Krystal Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.94

Current PE

34.65

Overvalued PE

52.01

Undervalued PE

-81.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

12.67

Current EV/EBITDA

26.37

Overvalued EV/EBITDA

59.14

Undervalued EV/EBITDA

-33.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

164.70

Current PS

13.79

Overvalued PS

744.30

Undervalued PS

-414.90

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KRYS News & Events

Events Timeline

No data

News

1.0

11-26Globenewswire

Krystal Biotech CEO to Participate in 8th Annual Evercore Healthcare Conference

8.0

11-04NASDAQ.COM

Significant Options Activity on Tuesday: ANDE, KRYS, CRWD

9.5

11-03NASDAQ.COM

Krystal Biotech (KRYS) Third Quarter 2025 Earnings Report Transcript

People Also Watch

Frequently Asked Questions

What is Krystal Biotech Inc (KRYS) stock price today?

The current price of KRYS is 245.24 USD — it has increased 0.24 % in the last trading day.

What is Krystal Biotech Inc (KRYS)'s business?

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

What is the price predicton of KRYS Stock?

What is Krystal Biotech Inc (KRYS)'s revenue for the last quarter?

Krystal Biotech Inc revenue for the last quarter amounts to 97.80M USD, increased 16.65 % YoY.

What is Krystal Biotech Inc (KRYS)'s earnings per share (EPS) for the last quarter?

Krystal Biotech Inc. EPS for the last quarter amounts to 2.66 USD, increased 192.31 % YoY.

What changes have occurred in the market's expectations for Krystal Biotech Inc (KRYS)'s fundamentals?

How many employees does Krystal Biotech Inc (KRYS). have?

Krystal Biotech Inc (KRYS) has 275 emplpoyees as of December 15 2025.

What is Krystal Biotech Inc (KRYS) market cap?

Today KRYS has the market capitalization of 7.09B USD.